Navigation Links
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
Date:12/16/2013

DUBLIN, Dec. 16, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/k8hhr8/peptide) has announced the addition of the "Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body.

Likewise, peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses.

This report analyzes the peptide therapeutics market by types of applications (cancer, metabolic, neurological diseases and others), route of administration, by types (innovative and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and technology. Each of these markets is analyzed by studying the current and future market scenario, with estimation for the period 2010 - 2018 in terms of value in USD million.

Key Topics Covered:

1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

2 Executive Summary

3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.3 Restraints & challenges
3.4 Opportunities
3.5 Porters five forces analysis
3.6 Market attractiveness analysis
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

4 Global Peptide Therapeutics Market Analysis, By Applications

5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.2 Parenteral Route
5.3 Oral Route
5.4 Pulmonary Route
5.5 Mucosal Route
5.6 Others (Intradermal & Nasal)

6 Peptide Therapeutics Market - Generic & Innovative Segments
6.1 Introduction
6.2 Peptide Therapeutics - Innovative market
6.3 Peptide Therapeutics - Generic market

7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics - In-house market
7.3 Contract Manufacturing Organizations (CMO)

8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.2 Solid Phase Peptide Synthesis (SPPS)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.4 Hybrid Technology

9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia
9.5 Rest of World

10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.3 Market share by key players in CMO segment

11 Recommendations
11.1 Success strategies
11.2 Barriers to be considered

12 Company Profiles

Companies Mentioned:

  • Amgen, Inc.
  • Amylin Pharmaceuticals LLC Bristol-Myers Squibb (BMS)
  • AstraZeneca PLC
  • Bachem Holding AG
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Ipsen
  • Lonza Inc.
  • Merck & Co.
  • Novartis AG
  • Novo-Nordisk A/S
  • Peptisyntha
  • Pfizer, Inc.
  • PolyPeptide Group.
  • Roche
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/k8hhr8/peptide

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
2. Poster & Abstract Entitled 1H-MRS & FDG-PET Studies in the SOD1 G93A - the Use of Stabilized Peptides as a Rationale for Future Treatment in ALS Presented During Annual Northeast ALS Consortium Meeting
3. US Peptides Discusses the Benefit of Human Growth Hormone
4. CEM Wins Peptide Patent Dispute with Biotage
5. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
7. US Peptides Discusses the Benefit of Human Growth Hormone and IGF-1
8. Innovative Research Collaboration to Advance Next-Generation Methods in Peptide Discovery for Cosmeceuticals
9. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
10. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
11. US Peptides Discusses IGF 1 in new article series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 ... and M 1 receptor selectivity   ... StaR® technology, which has entered clinical development as ... with dementia and schizophrenia.   --> ... technology, which has entered clinical development as a ...
(Date:2/9/2016)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... quarter ended December 31, 2015. ... Highlights , Revenue of $36.5 million compared to ... Domestic Radiation Measurement services revenues increased 2.8% year-over-year ...
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... ... ... The recreational use of marijuana has been legal in Colorado for over ... restrictions as to where they can smoke pot. , As Colorado’s website ... not be consumed openly or publicly.” , Given the momentum of the marijuana legalization ...
(Date:2/10/2016)... , ... February 09, 2016 , ... A new leadership ... Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior ... a 2003 graduate of FHU and the creator of GO! Camp, has been named ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. ... are delighted to welcome a new addition to their growing practice. Beginning this ... as a nurse practitioner performing cosmetic procedures including injectables, fillers and ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... concussion, yet the cause of injury may be one of many possible sources: ... PT Continuing Education Course , Mastering Rehab Solutions for the Complexities ...
Breaking Medicine News(10 mins):